Prognostication of ER-positive HER2-negative breast cancer is critical for decision making on adjuvant therapy. Many cancer patients are cured by local therapy, with surgery and radiotherapy, and endocrine therapy alone.
Confidently identifying patients who are cured so they can safely avoid chemotherapy is essential to minimise overtreatment. Several commercially available gene expression genomic classifiers are available to help identify cancers that are at such low risk of recurrence, that chemotherapy could not provide a meaningful improvement in outcome.
An unanswered question has been whether these genomic classifiers can give more information than just prognosis. In particular, can they confidently identify tumors that are insensitive to chemotherapy, such that even if the estimated risk of relapse based on clinicopathologic factors is sufficient to consider a course of chemotherapy, they can provide a classification that allows chemotherapy to be omitted from the patients' management?
Of the many genomic classifiers, the 21-gene Recurrence Score (RS; OncotypeDX), which has now been used in well over 500,000 patients 1 , had retrospective data from the NSABP B20 randomised trial of tamoxifen±chemotherapy that suggested that cancers with an old intermediate score (RS 18-30 and 10-year risk of distant recurrence of 11-21%) might be relatively insensitive to chemotherapy 2 . There has been uncertainty about the interpretation of that finding: it was derived from a retrospective, secondary analysis of a patient population that contributed samples to the training of the RS and the intermediate risk group comprised only 134 patients of which just 45
were from the tamoxifen alone arm. In contrast to that small study, an EBCTCG overview analysis of about 100,000 patients, including about 10,000 randomised to anthracycline or no chemotherapy, found no difference in the proportional reductions in risk of recurrence between any subgroups including those defined by histopathologic grade, ER versus negativity or level of ER positivity 3 . The EBCTCG findings surprised many since they are in stark contrast with the strong correlations these markers show with response to chemotherapy in the neoadjuvant setting 4 . Oncologists regularly seeing patients responding or not to neoadjuvant chemotherapy according to these biologic factors may be receptive to the concept of molecular predictors of long-term benefit from adjuvant chemotherapy, while evidence for such differences is slim at best.
The observation of possible prediction of chemotherapy sensitivity in the B20 study was sufficiently important for the TAILORx study to be designed to test The low breast cancer event rate for the study challenges the interpretation of its results. With 98% of patients in the endocrine only arm being free from distant recurrence at 5 years, the study has not been able to address whether intermediate risk cancers are chemotherapy sensitive, the original objective of the study. Instead patients in the randomized population recruited had such a good prognosis, chemotherapy was irrelevant. This is a very positive outcome for patients, with node-negative disease and tumors similar to those recruited into the randomised part of the study but it poses challenges to the generalizability of the finding to patients with higher stages of disease. 14 . Similarly, the 98.7% 3-year iDFS of a cohort of patients with small HER2+ tumours treated with paclitaxel and trastuzumab excludes meaningful benefit from adding more toxic chemotherapeutics 15 . Such cohort studies will likely report many years earlier than non-inferiority studies. Additionally, if the cancer event-rate in a noninferiority trial is substantially lower than anticipated, the study may not address the original objective. It is therefore highly important to ensure the risk profile of patients recruited will give the anticipated event rate, with the data monitoring committee primed to monitor this. where astrological star sign associated with benefit from aspirin after a myocardial infarction 16 . Examples are frequently observed in cancer trials; for example patients with HER2-positive non-visceral disease derived no benefit from pertuzumab in overall survival in the CLEOPATRA trial 17 . Such chance observations are frequent in subgroup analyses.
Of note the young patient subgroup analysis in TAILORx was retrospective, not pre-planned, and presents one subgroup (age) further subdivided by ranges of RS (11-15, 16-20 and 21-25) . The analysis suggested that premenopausal patients with an RS of 16 or greater may in contrast to the rest of the randomised population derive benefit from chemotherapy 5 . Yet the number of distant recurrences in the <=50 RS subgroups is very small, 16, 27 and 26 events respectively. We suggest that this should be considered a hypothesis-generating result. The Oxford EBCTCG meta-analyses in unselected patients, with many thousands of events, suggests moderately worse prognosis for young women, and modestly greater benefit from chemotherapy, but no major differences compared to older women 18 . Chemotherapy induced menopause in the <50 age group may also have contributed to the observed effect, as the study pre-dated the SOFT and TEXT studies demonstrating the benefit of ovarian suppression in premenopausal women 8, 9 ..
What does a practicing clinician do with the results of the TAILORx study? We expect this to be the subject of future guidelines, and we give our view as an interim measure. 8, 9 .
In summary and conclusion, the TAILORx study has been one of the most 
